Sanofi on an acquisition roll, making bid for Ablynx

29 January 2018

Announcing a second takeover bid in a matter of a week, French pharma major Sanofi (Euronext: SAN) today revealed that it has entered into a definite agreement to acquire Belgium biotech firm Ablynx (Euronext Brussels: ABLX), sending the latter’s shares up 19.6% to 44.40 euros.

Sanofi has offered to acquire all of the outstanding ordinary shares of Ablynx, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per share of 45 euros in cash, which represents an aggregate equity value of around 3.9 billion euros ($4.85 billion).

The proposed deal trumps one earlier this month from Danish diabetes care giant Novo Nordisk (NOV: N) of around $3.1 billion, which Ablynx rejected as undervaluing the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK